Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2.
10.3346/jkms.2014.29.3.351
- Author:
Ye Hwan KIM
1
;
Won Tae KIM
;
Pildu JEONG
;
Yun Sok HA
;
Ho Won KANG
;
Seok Joong YUN
;
Sung Kwon MOON
;
Yung Hyun CHOI
;
Isaac Yi KIM
;
Wun Jae KIM
Author Information
1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. wjkim@chungbuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Urinary Bladder Neoplasms;
USP18 Protein, Human;
DGCR2;
Survival;
Gene Expression Profiling
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Biological Markers/metabolism;
Carrier Proteins/genetics/metabolism;
Endopeptidases/genetics/*metabolism;
Female;
Gene Expression Profiling;
Humans;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Muscle Neoplasms/*secondary;
Neoplasm Invasiveness;
Neoplasm Staging;
Platelet Glycoprotein GPIb-IX Complex/genetics/*metabolism;
Predictive Value of Tests;
ROC Curve;
Regression Analysis;
Risk Factors;
Urinary Bladder Neoplasms/*diagnosis/metabolism/*mortality/pathology
- From:Journal of Korean Medical Science
2014;29(3):351-356
- CountryRepublic of Korea
- Language:English
-
Abstract:
We performed gene expression profiling in bladder cancer patients to identify cancer-specific survival-related genes in muscle invasive bladder cancer (MIBC) patients. Sixty-two patients with MIBC were selected as the original cohort and another 118 MIBC patients were chosen as a validation cohort. The expression of USP18, DGCR2, and ZNF699 genes were measured and we analyzed the association between gene signatures and survival. USP18 and DGCR2, were significantly correlated to cancer-specific death (P=0.020, P=0.007, respectively). Cancer-specific survival in the low USP18 or DGCR2 expression group was significantly longer than the high expression group (P=0.018, P=0.006, respectively). In multivariate Cox regression analysis, a combination of USP18 and DGCR2 mRNA expression levels were significant risk factors for cancer-specific death (HR, 2.106; CI, 1.043-4.254, P=0.038). Overall survival and cancer-specific survival rates in the low-combination group were significantly longer than those in the high-expression group (P=0.001, both). In conclusion, decreased expressions of USP18 and DGCR2 were significantly associated with longer cancer-specific survival, and also the combination of two genes was correlated to a longer survival for MIBC patients. Thus, the combination of USP18 and DGCR2 expression was shown to be a reliable prognostic marker for cancer-specific survival in MIBC.
